VivoSeq
Oncology

Acute Leukemia

144

Pipeline Programs↗

34

Active Trials↗

53

Companies Involved↗

Acute Leukemia is a highly competitive landscape with 144 programs across 53 companies. The most active players are Sanofi, Merck & Co., Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved with 21 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

76/100

Pipeline Velocity

36/100

Mech. Concentration

10/100

Completion Rate

65/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

4 programs

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 1S

Syndax Pharmaceuticals

1 program

Phase 1P

PTC Therapeutics

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

131 of 157 classified programs — the dominant modality here.

17%ALL OTHERSCell therapy138%Protein / enzyme74%Monoclonal antibody43%Antibody–drug conjugate1<1%Vaccine1<1%

Small molecule leads; the ring shows all 157 classified programs, each share of the total. Modality classified for 99% of 174 pipeline programs.

Analysis

Trial Status

145

clinical trials

Completed56 · 39%
Unknown status25 · 17%
Terminated22 · 15%
Recruiting21 · 14%
Withdrawn8 · 6%
Not yet recruiting8 · 6%
Other5 · 3%

Clinical Trials

Trial Activity

145 trials

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Recruiting·PPeking University People's Hospital·Phase 2/3·NCT03793517·55 enrolled
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Recruiting·—·Phase 1·NCT06575296·27 enrolled
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
Recruiting·KKing Faisal Specialist Hospital & Research Center·Phase 3·NCT04314219·264 enrolled
Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
Recruiting·TTata Memorial Centre·Phase 2·NCT06058572·166 enrolled
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07101497·60 enrolled
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Recruiting·WWest Virginia University·Phase 2·NCT07222579·78 enrolled
BY002 IIT Study in R/R Acute Leukemia
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07270770·18 enrolled
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06816134·48 enrolled
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT03326921·24 enrolled
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Recruiting·—·Phase 1·NCT03826992·21 enrolled
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
Recruiting·NNational University Hospital, Singapore·Phase 1·NCT05038696·40 enrolled
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Recruiting·PPedAL BCU, LLC·Phase 1·NCT06376162·20 enrolled
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06397027·22 enrolled
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT07295951·10 enrolled
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Recruiting·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 1/2·NCT04988555·606 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)